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fluid retention (C-PET 22% and BIG1-98 7%) and vaginal dry-
ness (C-PET 30% and BIG1-98 3%). Similar differences were 
observed in the metastatic and adjuvant setting.  Conclu-
sions: A simple tool like the C-PET questionnaire is able to 
reflect the treatment burden of endocrine therapies and 
may be helpful to improve communication between pa-
tients and care providers. Some symptoms were significant-
ly more often reported by the women in the C-PET than by 
physicians in pivotal trials.  Copyright © 2009 S. Karger AG, Basel 
 Introduction 
 Hormonal therapy has become the therapy of choice 
for women with breast cancer who are considered likely 
to respond to endocrine therapy, aiming to improve sur-
vival and quality of life. In patients with breast cancer, 
health care professionals rank side effects and distress 
caused by hormonal treatment frequently lower than 
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 Abstract 
 Objectives: The purpose of this investigation was firstly to 
assess the overall frequency of subjectively experienced 
symptoms self-reported by patients receiving endocrine 
therapy and secondly to compare these symptoms with side 
effects assessed by clinicians in pivotal trials.  Methods: Un-
selected patients with early and advanced breast cancer re-
ceiving endocrine therapy were approached consecutively 
during a routine outpatient visit. They received a question-
naire called  Checklist for Patients with Endocrine Therapy (C-
PET), a validated self-assessment tool to determine prespec-
ified symptoms associated with endocrine therapy. Data on 
toxicity were also obtained from previously published trials. 
 Results: 405 patients were approached and 373 agreed to 
participate in this study. Some symptoms were significantly 
more often recorded by the women in the adjuvant setting 
completing the C-PET than by physicians’ reports in pivotal 
trials: hot flushes/sweats (C-PET 70%, ATAC 40% and BIG1-98 
38%), low energy (C-PET 45%, ATAC 15% and BIG1-98 9%), 
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those associated with chemotherapy  [1] , suggesting that 
the side effects do not significantly affect quality of life  [2] , 
although hormonal therapy is prescribed for a longer time 
period than chemotherapy. This perception is supported 
by a previously published study demonstrating that health 
care professionals underreport side effects related to hor-
monal treatment  [3] . However, side effects of hormonal 
therapy play a greater role in the interpretation of major 
adjuvant trials as previously, because the toxicity profile 
of the different treatment options is important for the op-
timal choice of treatment, which has to be balanced against 
a minimal survival advantage. Usually, toxicity and toler-
ability profiles of a treatment have been inferred from 
physician-recorded adverse events, but controversy exists 
regarding the accurate assessment of symptoms.
 The primary objective of this investigation was to as-
sess the overall frequency of subjectively experienced 
symptoms by breast cancer patients receiving endocrine 
therapy, and the secondary objective was to compare it 
with frequencies reported in pivotal trials. Whereas 
breast cancer patients in the former setting received en-
docrine therapy in a very informal manner outside of a 
study setting and were therefore self-reporting their 
symptoms, side effects in the latter were assessed by clini-
cians and not by the patients.
 Patients and Methods 
 This prospective, cross-sectional investigation was conducted 
in women with both early and advanced breast cancer. The wom-
en were approached during a routine outpatient visit. The study 
forms containing the self-explanatory leaflet regarding this study, 
an informed consent form and the study questionnaires were giv-
en to all women receiving endocrine therapy in a participating 
center. The questionnaire was completed prior to their consulta-
tion with the doctor. Upon completion of the questionnaire, the 
women were offered the opportunity to discuss their side effects 
with their doctor.
 All women with breast cancer who were receiving any form 
and any line of hormonal therapy were included; only patients 
concomitantly receiving chemo- and immunotherapy were ex-
cluded from the study. During the consultation the doctor re-
ceived the completed questionnaire and provided the informa-
tion pertaining to the type and indication for the hormonal ther-
apy (early or advanced stage), and previous treatment with 
ovarian ablation and/or chemotherapy. The menopausal status 
was not required as it was retrospectively determined by age 
( ! / 1 50 years) and/or the type of treatment.
 The women completed the  Checklist for Patients with Endo-
crine Therapy (C-PET)  [4, 5] , an interactive self-assessment tool 
which was developed and tested by a European Task Force and is 
also available in a validated German version. It records the fre-
quency of 13 prespecified symptoms associated with endocrine 
therapy. It only focuses on the incidence of an event without grad-
ing its severity. In addition to the C-PET, International Breast Can-
cer Study Group (IBCSG)/Linear Analogue Self-Assessment Scales 
were utilized to address the side effects of hormonal therapy and 
treatment burden, the results being discussed elsewhere  [6] .
 For comparison, we selected some pivotal trials representing 
key trials in the field of endocrine therapy in our opinion. The 
toxicity data of the pivotal trials were retrieved from the publica-
tions and, in the case of BIG1-98  [7] , additional information on 
side effects, e.g. nausea, fatigue/lethargy, edema and vaginal ir-
ritation, was obtained from an unpublished report prepared for 
health authorities.
 This multi-institutional study was conducted in oncology out-
patient departments of four regional teaching hospitals and by 
four affiliated oncologists working in private practice in Eastern 
Switzerland. Ethical approval was provided by the local ethical 
committees.
 Exact confidence intervals for proportions were calculated us-
ing Sterne’s method  [8] and comparisons between groups were 
made using Fisher’s exact test. For comparisons between early and 
advanced breast cancer ( table 1 ), p  ! 0.05 was considered to be 
statistically significant. When comparing symptom frequency 
between different trial data, Bonferroni-corrected (per symptom) 
confidence intervals were employed for the number of trials un-
der consideration to maintain a global significant level of 0.05. 
More specifically, in  table 2 confidence intervals were computed 
using a significance level of 0.05/2 = 0.025 and in  table 3 using 
0.05/3 = 0.016.
 Results 
 Patient Characteristics 
 Of the 405 patients approached, 373 agreed to partici-
pate in this study (92%). The reasons for declining varied: 
17 patients gave no reason, 5 did not understand due to 
language difficulties, 6 gave their clinical condition as a 
reason, 2 had no time, 1 had forgotten her glasses and 1 
was apparently psychotic.
 At the time of study entry, the median age of the 373 
study patients was 61 years (range 29–88 years) and the 
20th percentile was 51 years; 302 and 71 patients were treat-
ed in adjuvant and metastatic setting, respectively, and 213 
patients had received chemotherapy before endocrine ther-
apy. The types of hormonal therapies used are listed in  fig-
ure 1 . The largest group receiving one form of endocrine 
therapy comprised the 200 postmenopausal women who 
received tamoxifen: 31 patients were in blinded studies 
comparing tamoxifen with an aromatase inhibitor.
 Frequency of Symptoms 
 Table 1 lists the frequencies of symptoms reported by 
the women. Only the reporting of  weight gain and  hot 
flushes/sweats was significantly greater for those receiv-
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ing adjuvant therapies compared to those with metastat-
ic disease. No significant difference in the frequency of 
reports was evident regarding the other symptoms. Like-
wise, we found no significant difference in the frequen-
cies of C-PET-reported adverse events between post-
menopausal patients taking antiestrogens and those tak-
ing aromatase inhibitors.
 Comparisons with Pivotal Trials 
 We compared the frequencies of adverse events found 
in our study with those reported in several pivotal stud-
ies.
 Firstly, we compared the data from our largest homog-
enous group of patients, i.e. postmenopausal women in 
the adjuvant setting receiving tamoxifen, with the con-
Table 1. Frequencies of side effects reported by breast cancer patients in the C-PET
Side effects 
C-PET 
Early stage (n = 302) Advanced stage (n = 71) All patients (n = 373) p value 
Fisher’s 
exact test1n % CI n % CI n % CI
Vaginal dryness 106 35 29–42 20 28 17–41 126 34 28–40 0.33
Vaginal bleeding 7 3 1–5 2 3 0–11 9 2 1–5 0.68
Breathlessness 50 17 11–22 14 20 11–32 64 17 13–22 0.60
Skin rash 34 11 8–16 3 4 1–13 37 10 7–14 0.08
Decreased sex drive 89 29 24–36 20 28 17–41 109 29 24–35 0.89
Irritability 53 18 13–23 13 18 10–31 66 18 14–23 0.86
Fluid retention 61 20 15–26 12 17 9–29 73 20 15–25 0.62
Low energy 138 46 39–52 35 49 36–63 173 46 41–52 0.60
Nausea 28 9 6–14 9 13 6–24 37 10 7–14 0.38
Weight gain 147 49 42–55 20 28 17–41 167 45 39–51 0.002
Hot flushes/sweats 220 73 67–78 40 56 43–69 260 70 64–75 0.009
CI = Exact confidence interval for the proportion of patients indicating the symptom.
1 Adjuvant vs. metastatic, unadjusted for multiple comparisons.
Patients offered
participation (n = 405)
Participating patients (n = 373)
Not willing or unable to 
participate (n = 32)
Metastatic (n = 71)
Premenopausal (n = 58)
Adjuvant (n = 302)
TAM (n = 35)
Other antiestrogens (n = 2)
GnRH (n = 11)
GnRH + TAM or AI (n = 10)
TAM (n = 200)
Other antiestrogens (n = 5)
AI (n = 13)
BIG-1 (n = 25)
Gestagen (n = 1)
Premenopausal (n = 6)
TAM (n = 2)
Other antiestrogens (n = 1)
GnRH + TAM or AI (n = 3)
TAM (n = 22)
Other antiestrogens (n = 3)
AI (n = 33)
Gestagen (n = 1)
TAM/Arimidex blinded (n = 6)
Postmenopausal (n = 65) Postmenopausal (n = 244)
 Fig. 1. Patient characteristics. TAM = Tamoxifen; AI = aromatase inhibitor. 
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trol arms of two of the most important and largest studies 
comparing an aromatase inhibitor with tamoxifen  [7, 9] . 
Not all of the symptoms recorded by the C-PET were pub-
lished in these two studies; however, we received unpub-
lished data from the BIG1-98 trial.  Table 2 demonstrates 
that  hot flushes/sweats were significantly more often re-
ported by our patients compared with the pivotal studies: 
 70% using C-PET versus 40 and 38% reported in the 
ATAC and BIG1-98, respectively.  Low energy was report-
ed by 45 (C-PET) versus 15 and 9% (ATAC and BIG1-98, 
respectively) , fluid retention  by 22 (C-PET) versus 7% 
(BIG1-98) and vaginal dryness  by 30 (C-PET) versus 3% 
(BIG1-98). In contrast,  vaginal bleeding was reported sig-
nificantly less in our group of patients (2% with C-PET 
vs. 8 and 10% in the ATAC and BIG1-98 trial, respective-
Table 3. Frequencies of side effects following treatment with 
tamoxifen or aromatase inhibitors mentioned in C-PET com-
pared to pivotal trials in postmenopausal patients with metastat-
ic breast cancer
Side effects    0  50  100% n/total n % CI, %
Hot flushes
C-PET 32/61 52 37–68
Nabholtz et al. [11] 115/352 33 27–39
Bonneterre et al. [10] 137/665 21 17–25
Mouridsen et al. [12] 151/910 17 14–20
Nausea
C-PET 6/61 19 3–23
Nabholtz et al. [11] 114/352 32 26–39
Bonneterre et al. [10] 86/665 13 10–16
Mouridsen et al. [12] 138/910 15 12–18
Vaginal dryness/irritation
C-PET 15/61 25 13–41
Nabholtz et al. [11] 15/352 4 2–8
Bonneterre et al. [10] 13/665 2 1–4
Mouridsen et al. [12]
Breathlessness
C-PET 10/61 16 7–31
Nabholtz et al. [11]
Bonneterre et al. [10]
Mouridsen et al. [12] 128/910 14 11–17
Weight gain
C-PET 15/61 25 13–41
Nabholtz et al. [11] 7/352 2 1–5
Bonneterre et al. [10] 12/665 2 1–4
Mouridsen et al. [12]
Low energy/lethargy
C-PET 30/61 49 33–65
Nabholtz et al. [11] 7/352 2 1–5
Bonneterre et al. [10] 13/665 2 1–4
Mouridsen et al. [12] 99/910 11 9–14
Vaginal bleeding
C-PET 0/61 0 0–8
Nabholtz et al. [11] 9/352 3 1–6
Bonneterre et al. [10] 12/665 2 1–4
Mouridsen et al. [12]
Irritability/mood/depression
C-PET 10/61 16 7–31
Nabholtz et al. [11] 23/352 7 4–11
Bonneterre et al. [10] 32/665 5 3–7
Mouridsen et al. [12]
Table 2. Frequencies of side effects following tamoxifen treatment 
mentioned in C-PET compared to pivotal trials in postmenopaus-
al patients with early breast cancer
Side effects 0 50 100% n/total n % CI, %
Hot flushes/sweats
C-PET 139/200 70 61–77
BIG1-98 1,516/3,988 38 36–40
ATAC 1,229/3,094 40 38–42
Low energy/lethargy
C-PET 90/200 45 37–54
BIG1-98 345/3,988 9 8–10
ATAC 466/3,094 15 14–17
Vaginal discharge
C-PET 25/200 12 8–19
BIG1-98
ATAC 354/3,094 11 10–13
Irritability/mood/depression
C-PET 33/200 16 11–24
BIG1-98
ATAC 469/3,094 15 14–17
Nausea
18/200 9C-PET 5–15
BIG1-98 418/3,988 10 9–12
ATAC 315/3,094 10 9–12
Vaginal dryness/irritation
C-PET 60/200 30 23–38
BIG1-98 122/3,988 3 2–4
ATAC
Vaginal bleeding
C-PET 4/200 2 0–6
BIG1-98 413/3,988 10 9–12
ATAC 253/3,094 8 7–9
Fluid retention/edema
C-PET 43/200 22 15–29
BIG1-98 288/3,988 7 6–8
ATAC
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ly). The other side effects were comparable between the 
two groups. Of note, in the pivotal studies, toxicity data 
were collected cumulatively whereas in our cross-sec-
tional investigation only the question ‘are you suffering 
from one of these symptoms…’ was asked.
 Secondly, we compared the responses of our group of 
postmenopausal women with metastatic disease who re-
ceived either tamoxifen or an aromatase inhibitor to 
those of three pivotal studies investigating tamoxifen 
versus anastrozole or letrozole as first-line therapy for 
postmenopausal women with advanced breast cancer 
 [10–12] . To ensure a fair comparison, we pooled the con-
trol and the investigational arm from the pivotal studies 
and did likewise in our patient group including patients 
from a blinded trial. Again, not all symptoms recorded 
with C-PET were recorded in all the pivotal studies. As 
shown in  table 3 ,  hot flushes/sweats, low energy, weight 
gain  and vaginal dryness  were significantly more fre-
quently reported in our cross-sectional study.
 Discussion 
 The self-reported frequency of symptoms experienced 
by our study patients was considerably increased, amount-
ing to 70% for  hot flushes/sweats , 45% for  low energy and 
30% for  vaginal dryness , for example. Surprisingly, we did 
not find a significant difference in reported side effects 
between early and advanced stage of the disease apart 
from  weight gain and  hot flushes/sweats , suggesting that 
patients with advanced disease do not care so much about 
these symptoms or rather have problems to maintain 
their weight in a more advanced stage. Our study cohort 
was too small to reveal a significant difference between 
different treatment options.
 The strength of our study was certainly the ease of ac-
cess to possible participants, the user-friendly question-
naire and the collection of data from all women receiving 
endocrine therapy during the observation period of this 
study. Furthermore, women participating in this study 
were derived from different care settings, including pri-
vate oncologists, non-academic institutions and a region-
al cancer center. Another advantage was the ease to com-
plete and validate the findings due to the data collection 
tool utilized. Finally, complete data were also obtained 
from the small non-participating group. The C-PET is a 
tool which enables to assess adverse events without the 
patient being influenced by caregivers, as it was complet-
ed by the patient without the help of nurses and before 
consulting the doctor, whereas adverse events in clinical 
trials are usually collected by doctors, nurses and/or the 
study coordinators.
 A weakness of our study was the lack of definition re-
garding the patient group for practical reasons which re-
sulted in missing prospective data concerning meno-
pausal status, extent of disease and receptor status. How-
ever, receptor status was probably irrelevant for endocrine 
side effects. There was some difficulty regarding the 
wording caused by the translation into German when 
making a comparison between pivotal studies and ours; 
for instance,  low energy  in our investigations was com-
pared with  lethargy (Nabholtz et al.  [11] and Bonneterre 
et al.  [10] ) and  fatigue (BIG1-98 and ATAC),  vaginal dry-
ness with  vaginal irritation  (BIG1-98) and  fluid retention 
 with edema  (BIG1-98).
 Of course, the comparison between results of our 
cross-sectional study and those observed in pivotal trials 
has some limitations and cannot replace a direct com-
parison between self-reported symptoms by patients and 
symptoms assessed by physicians in a specifically de-
signed study to investigate this question. In our cross-
sectional survey, women were asked at different time 
points and at different stages of disease compared to the 
selected patients entered into the trials. Furthermore, as 
mentioned above, in the pivotal studies toxicity data were 
collected cumulatively whereas our trial was a cross-sec-
tional investigation. Also, the comparison with pivotal 
trials is in some way arbitrary. However, the significantly 
different incidences in some symptoms observed between 
our study and the pivotal studies cannot solely be ex-
plained by the above-mentioned two features. Even the 
results of the comparisons between the adjuvant and 
metastatic setting in our study and the pivotal trials 
showed little variation.
 Some symptoms like  breathlessness, nausea  and mood 
changes are less clearly attributable to endocrine therapy 
and were reported with low frequency ( ! 20%) in both our 
study and the pivotal trials.
 Vaginal bleeding was the only symptom with a signif-
icantly lower incidence in our study group than in piv-
otal studies. It is reasonable that a medically clearly de-
fined symptom characterized by being more an incident 
than a chronic symptom is reported with lower frequen-
cy in our cross-sectional study than in the collection of 
cumulative toxicities in the pivotal trials.
 In our opinion, the most important finding was the 
much higher frequency of symptoms like  hot flushes/
sweats, weight gain, vaginal dryness, low energy  and fluid 
retention  reported by women in our study compared with 
those reported by physicians in the pivotal randomized 
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studies. These differences are striking. Some of these 
symptoms such as  hot flushes/sweats, weight gain and 
 vaginal dryness are subjective symptoms clearly assigned 
to endocrine therapy and postmenopausal status, with 
others, e.g.  low energy and  fluid retention , being more dif-
ficult to assign.
 The obvious explanation for the differences in the fre-
quency of reported events between the pivotal studies 
and ours could be that professionals do not document all 
the symptoms experienced by the patients. Many symp-
toms are also highly subjective, non-life-threatening and 
difficult to grade. As we know from several other publi-
cations, physician-guided symptom assessment is not 
sufficient to give an overall picture of the real side effects 
of endocrine treatments and is underestimating the real 
treatment burden  [3, 13] . Usually, investigators are cer-
tainly more interested in severe side effects like bone frac-
tures, or coronary or cerebral thrombosis, than in ill-de-
fined, uncomplicated and difficult-to-treat symptoms 
such as hot flushes, weight gain or low energy. However, 
especially these symptoms may significantly affect the 
patients’ quality of life. Since the authors, editors and reg-
ulatory agencies of previous studies were more interested 
in safety and survival than in quality-of-life data, not all 
of the endocrine therapy-related symptoms addressed in 
our study could be found in published pivotal studies. 
The frequency of weight gain, a disturbing, subjective 
symptom, can be easily compared to the objective weight 
changes in a future trial to address treatment burden of 
symptoms versus objective adverse events for example.
 Patients do not always discuss their symptoms with 
the doctor, possibly because they have already mentioned 
them during their previous consultation, or they perceive 
the doctor may not be interested in them or does not have 
enough time for less serious symptoms affecting well-be-
ing rather than safety. They may attribute the cause of 
their symptoms to menopause, the symptoms may not 
constantly disturb them, or it is a taboo to speak about 
particular symptoms, for example vaginal dryness and 
problems regarding intercourse  [14] . Other reasons in-
clude the patient’s feeling that the investigator is not the 
appropriate person to address these symptoms, e.g. a 
medical oncologist or surgeon instead of a gynecologist, 
and finally patients may be convinced that the doctor will 
not be able to improve specific symptoms or may even 
stop their treatment.
 Due to the many possible explanations for the find-
ings, questionnaires could be perceived to be an ideal 
screening tool for obtaining a more accurate picture of 
the true frequency of symptoms and their effect on the 
patient. However, then the same frequencies of symptoms 
should be reported in quality-of-life subdata obtained 
from studies. In fact, the ATAC study analyzed quality of 
life in a substudy  [15] . Here the symptom hot flushes/
sweats was subdivided into hot flushes (32%), cold sweats 
(11%) and night sweats (24%), thus rendering a compari-
son difficult, since several women were assessed repeat-
edly. However, vaginal dryness was reported only by 8% 
of the women, lack of energy by 20% and weight gain by 
23%, compared to 30, 45 and 49%, respectively, in our 
study. Only approximately one third of the women par-
ticipated in the quality-of-life subgroup of the ATAC 
study, implying that the participating women were se-
lected twice, first for the general trial and second for the 
substudy. Additionally, the aim of the ATAC trial was to 
compare the two drugs rather than to assess the impact 
of their adverse effects.
 Studies comparing existing tools, e.g. C-PET, EORTC 
QLQ 30 and BC module or IBCSG standard QOL ques-
tionnaires used in different settings (completed by pa-
tients alone before the consultation or with help of the 
care providers), will help to achieve a better understand-
ing of apparent or truly different results.
 In conclusion, we were able to demonstrate that high-
er frequencies of symptoms, e.g.  hot flushes/sweats, vagi-
nal dryness, weight gain, low energy  and  fluid retention , 
were reported by women receiving endocrine therapy in 
the C-PET tool than in previous pivotal studies. To accu-
rately describe subjective, non-life-threatening symp-
toms, a tool like this questionnaire (C-PET) is helpful, 
particularly to highlight potentially treatable symptoms 
before the consultation with the doctor. C-PET is a very 
simple and cost-effective questionnaire, short and feasi-
ble, not requiring intensive instruction. It could improve 
communication between patients and care providers re-
garding possible side effects. Such a simple instrument 
might therefore improve the quality of life of women on 
endocrine therapy.
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